A ROS-responsive decitabine prodrug compound and its preparation method and application
By developing a lipid composition that binds decitabine prodrug compounds with gene drugs with ROS-responsive, the problems of severe off-target toxicity and AML cell resistance in existing decitabine treatment methods were solved, and decitabine was achieved accurate release and efficient treatment of hematologic malignant tumors.
Patent Information
- Application Number
- CN202411274217.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-12
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2044-09-12
AI Technical Summary
The existing decetabine treatment methods have serious off-target toxic side effects, and AML cells promote drug resistance through inflammatory factor-related pathways and anti-apoptotic protein expression, resulting in poor treatment effects and high recurrence rates.
Develop a ROS-responsive decetabine prodrug compound, and builds a prodrug compound with precise release ability by combining decetabine with phosphatidylethanolamine compounds and ROS response bonds, and combines it with gene drugs. Prepare a lipid composition for the treatment of hematologic malignancy.
The precise release of decitabine is achieved, the off-target toxicity is reduced, the treatment effect of hematologic malignant tumors is improved, the occurrence of toxic and side effects is reduced, and the treatment effect is improved through multi-pathway and multi-target treatment methods.
Smart Images

Figure CN118791541B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a decitabine prodrug compound, in particular to a ROS-responsive decitabine prodrug compound, and also to a preparation method and application of the decitabine prodrug compound. Background Art
[0002] Acute myeloid leukemia (AML) is a highly heterogeneous type of hematological malignancy. It is a clonal abnormality of hematopoietic stem cells in the bone marrow, which leads to the accumulation of a large number of abnormally differentiated myeloid cells in the bone marrow. Although new treatments have emerged in the past, such as chemotherapy and bone marrow transplantation, which can control the disease in a short period of time, chemotherapy can cause serious off-target side effects, such as neutropenia and thrombocytopenia. In addition, AML cells also promote drug resistance by upregulating inflammatory factor-related pathways and the expression of anti-apoptotic proteins, resulting in poor overall treatment effects for AML and a high relapse rate.
[0003] MicroRNA (miRNA) is a type of endogenous small RNA with a length of about 20-24 nucleotides. It has a variety of important regulatory effects in cells. It can regulate target mRNA by destroying the stability of target mRNA and inhibiting the translation of target mRNA. Each miRNA can have multiple target genes, and several miRNAs can also regulate the same gene. Therefore, selecting a suitable miRNA sequence can induce efficient and specific degradation of specific mRNA, block the expression of target genes, and thus achieve the purpose of treating specific diseases. When exogenous miRNA works, it must pass through the cell membrane to interact with mRNA inside the cell. However, the cell membrane, as a phospholipid bilayer, is negatively charged, which makes it difficult for negatively charged and hydrophilic miRNA to be taken up through passive diffusion. In addition, miRNA is easily degraded by nucleases that exist in large quantities in the blood, and its stability is very poor. Therefore, effective delivery of miRNA in vivo must rely on a suitable carrier.
[0004] Prodrugs, also known as prodrugs, are biologically inert compounds that are activated into pharmacologically active substances after administration. The application of prodrugs is usually to overcome pharmacokinetic barriers, such as poor solubility, poor absorption, and high first-pass metabolism; to overcome pharmacodynamic barriers, such as toxic side effects and poor efficacy. Among them, decitabine, as a methyltransferase inhibitor, is widely used in the clinical treatment of myelodysplastic syndrome and AML; its route of administration is intravenous injection, which requires daily administration and often causes severe off-target toxic reactions such as thrombocytopenia and anemia; the current improvement methods are mostly used in combination with other chemical drugs or monoclonal antibodies, but this combination is often used to enhance the efficacy and change the pharmacokinetic behavior, and cannot significantly reduce its off-target toxicity. There is a lack of research on the structural modification of first-line therapeutic drugs themselves to prepare prodrugs for the treatment of hematological malignancies. Therefore, new therapeutic drugs and methods are still urgently needed for the treatment of hematological malignancies. Summary of the invention
[0005] Purpose of the invention: The purpose of the present invention is to provide a ROS-responsive decitabine prodrug compound, and also to provide a method for preparing the above-mentioned ROS-responsive decitabine prodrug compound and its application in the preparation of a lipid composition for treating hematological malignancies.
[0006] Technical solution: The ROS-responsive decitabine prodrug compound of the present invention has the following structural formula: ;
[0007] Among them, X is or , n is an integer from 0 to 7;
[0008] Y is a ROS-responsive bond, including a thioketal, a boronate, a thioether bond, a ferrocene, a selenium-containing bond, or a tellurium-containing bond;
[0009] Z is a phosphatidylethanolamine compound, including distearoylphosphatidylethanolamine, dioleoylphosphatidylethanolamine, dimyristoylphosphatidylethanolamine, dilauroylphosphatidylethanolamine, and dipalmitoylphosphatidylethanolamine;
[0010] a is an ester bond or an amide bond between X and Y, and the structure is or ;
[0011] b is the connecting bond between Y and Z is an amide bond, and the structure is .
[0012] Among them, Y is preferably , , , , , , , , .
[0013] Among them, Z is preferably , , , , .
[0014] The ROS-responsive decitabine prodrug compound comprises the following structure: , , , , , , , , , , , , .
[0015] The preparation method of the above-mentioned decitabine prodrug compound comprises the following steps:
[0016] (1) A phosphatidylethanolamine compound and a compound having a ROS responsive group are subjected to an amidation reaction to prepare an intermediate compound 1: ;
[0017] (2) Decitabine and a linear amino acid with an amino group protecting group are reacted by esterification to prepare intermediate compound 2: ;
[0018] (3) Removing the protecting group in the intermediate compound 2 molecule by acid-base hydrolysis reaction to prepare intermediate compound 3: ;
[0019] (4) The intermediate compound 1 is reacted with the intermediate compound 3 through an amidation reaction or the intermediate compound 1 is reacted with decitabine through an esterification reaction to prepare a decitabine prodrug represented by the general formula I.
[0020] The above-mentioned decitabine prodrug compound can also be used in the preparation of drugs for treating hematological malignancies.
[0021] Wherein, the blood malignancies include acute myeloid leukemia, myelofibrosis, myelodysplastic syndrome, lymphoma or chronic myeloid leukemia.
[0022] Wherein, the drug is a lipid composition loaded with a decitabine prodrug compound; the lipid composition consists of an ionizable lipid material, other lipid materials and a decitabine prodrug compound.
[0023] The drug may also be loaded with a gene drug, and the gene drug is selected from one or more of siRNA, miRNA, mRNA, ASO, cricRNA, ssRNA, shRNA, and ssDNA.
[0024] Among them, in the lipid composition, the mass ratio of ionizable lipids, other lipid materials, gene drugs and decitabine prodrug compounds is 10~50:10~60:0~4:10~40.
[0025] The ionizable lipid is one of Dlin-MC3-DMA, SM-102, and ALC-0315, preferably ALC-0315; the other lipid materials are dioleoylphosphatidylcholine (DOPC), hydrogenated soybean phosphatidylglycerol (HSPG), egg phosphatidylglycerol (EPG), egg phosphatidylinositol (EPI), hydrogenated soybean phosphatidylethanolamine (HSPE), phosphatidylethanolamine (EPE), soybean phosphatidylcholine (SPC), soybean phosphatidylglycerol (SPG ), soybean phosphatidylserine (SPS), soybean phosphatidylinositol (SPI), hydrogenated soybean phosphatidylserine (HSPS), soybean phosphatidylethanolamine (SPE), soybean phosphatidic acid (SPA), hydrogenated egg phosphatidylcholine (HEPC), hydrogenated egg phosphatidylglycerol (HEPG), egg phosphatidylserine (EPS), hydrogenated egg phosphatidylinositol (HEPI), hydrogenated egg phosphatidylserine (HEPS), hydrogenated phosphatidylethanolamine (HEPE), hydrogenated phosphatidic acid (HEPA) , hydrogenated soybean phosphatidylcholine (HSPC), hydrogenated soybean phosphatidylinositol (HSPI), hydrogenated soybean phosphatidic acid (HSPA), dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylinositol (DSPI), egg phosphatidylcholine (EPC), dimyristoylphosphatidylcholine (DMPC), dimyristoylphosphatidylglycerol (DMPG), dipalmitoylphosphatidylglycerol (DPPG), distearoylphosphatidylcholine (DSPC), distearoylphosphatidylglycerol (DSPG), phosphatidic acid (EPA), dioleylphosphatidyl-ethyl DOPE, palmitoylstearoylphosphatidylcholine (PSPC), dipalmitoylphosphatidic acid (DPPA), palmitoylstearoylphosphatidylglycerol (PSPG), monooleoyl-phosphatidylethanolamine (MOPE), tocopherol, ammonium salts of fatty acids, ammonium salts of phospholipids, ammonium salts of glycerides, dilauroylethylphosphocholine (DLEP), distearoylphosphatidylserine (DSPS), dimyristoylethylphosphocholine (DMEP), dipalmitoylethylphosphocholine (DPEP) and distearoylethylphosphocholine (DSEP), N-(2, 3-di-(9- (Z)-octadecenyloxy)-prop-1-yl-N, N, N-trimethylammonium chloride (DOTMA), 1,2-Bis(oleoyloxy)-3-(trimethylammonium)propane (DOTAP), distearoylphosphatidylglycerol (DSPG), dimyristoylphosphatidic acid (DMPA), distearoylphosphatidic acid (DSPA), dimyristoylphosphatidylinositol (DMPI), dipalmitoylphosphatidylinositol (DPPI), dimyristoylphosphatidylserine (DMPS), dipalmitoylphosphatidylserine (DPPS), myristoyl lysophosphatidylcholine (M-LysoPC), palmitoyl lysophosphatidylcholine (P-LysoPC), stearoyl lysolecithin (S-lysoPC), distearoyl phosphatidylethanolamine-polyethylene glycol (DSPE-PEG), phosphatidylcholine-polyethylene glycol (PC-PEG), phosphatidylethanolamine-polyethylene glycol (PE-PEG), distearoyl phosphatidylcholine-polyethylene glycol (DSPC-PEG), cholesterol, lanosterol, sitosterol, stigmasterol, ergosterol and other functionalized phospholipids or sterol water-soluble derivatives. One or more.
[0026] Among them, the composition adopts the preparation method including liposome extrusion method, thin film hydration method, nanoprecipitation method, microfluidics, impact jet mixing method, thin film dispersion method, reverse phase evaporation method, multiple emulsion method and solvent injection method, hot melt method, freeze drying method, spray drying method, supercritical reverse phase evaporation method, dialysis method, solvent volatilization method or freeze drying method.
[0027] Principle of the invention: The ROS-responsive decitabine prodrug compound of the present invention connects the chemotherapy drug decitabine to the lipid chain through a thioketal bond to construct a prodrug compound with ROS response, which can achieve precise release and reduce the off-target toxicity of chemotherapy drugs; in addition, due to the presence of lipid chains, when preparing lipid compositions, drugs can be embedded therein as structural components, ensuring higher loading efficiency while extending the in vivo circulation time. The simultaneous delivery of prodrugs and gene drugs using lipid compositions can further improve drug efficacy, achieve precise drug release, and reduce the occurrence of toxic side effects; the combination of decitabine prodrug compounds and gene drugs can achieve multi-pathway and multi-target treatment, thereby better playing the role of treating blood malignancies.
[0028] Beneficial effects: Compared with the prior art, the present invention has the following significant advantages: (1) The ROS-responsive decitabine prodrug compound of the present invention has low toxicity and the ability of precise release, and the prepared lipid composition has a higher loading rate and a longer circulation in the body; (2) The combination of the ROS-responsive decitabine prodrug compound and the gene drug improves the therapeutic effect of hematological malignancies; (3) The preparation method is simple, the raw materials are easy to obtain, the yield is high, and it is suitable for large-scale production and supply. BRIEF DESCRIPTION OF THE DRAWINGS
[0029] Figure 1 The synthetic route of step (1) in Example 1;
[0030] Figure 2 The synthetic route of step (2) in Example 1;
[0031] Figure 3 The synthetic route of step (3) in Example 1;
[0032] Figure 4 is the hydrogen nuclear magnetic resonance spectrum of the ROS-responsive decitabine prodrug compound DSPE-TK-DCA-Ala of the present invention;
[0033] Figure 5 is the particle size distribution diagram of lipid nanoparticles in Example 4;
[0034] Figure 6 is the particle size distribution diagram of lipid nanoparticles in Example 5;
[0035] Figure 7 This is the nucleic acid electrophoresis diagram of the plasma stability of the lipid nanoparticles in Example 3;
[0036] Figure 8 is a cumulative release curve of lipid nanoparticles under different conditions in Example 4;
[0037] Fig. 9 This is a synergy index diagram of the decitabine prodrug compound of the present invention and the gene drug in the lipid nanoparticles in Example 4;
[0038] Fig.10 Statistical graph showing that lipid nanoparticles promote cell apoptosis in Examples 2 to 5. DETAILED DESCRIPTION
[0039] The technical scheme of the present invention is further described below in conjunction with the examples. The test materials used in the examples can all be purchased through conventional channels.
[0040] Example 1
[0041] The ROS-responsive decitabine prodrug compound of the present invention comprises the following steps: (1) the preparation process of the intermediate product DCA-Ala-NH2 is as follows: decitabine (DCA) (1 mmol, 228.1 mg) and Boc-β-alanine (Boc-β-Ala) (1.2 mmol, 226.9 mg) are dissolved in N,N-dimethylformamide (DMF), 4-dimethylaminopyridine (DMAP) (3 mmol, 366.5 mg) and 1-ethyl-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI) (3 mmol, 575.1 mg) are reacted at room temperature for 24 h; after the reaction is completed, the product is purified by column chromatography to obtain a yellow oily substance (379.4 mg, 95%), and DCA-Ala-Boc was obtained. DCA-Ala-Boc (1mmol, 399.4mg) was dissolved in 5mL of dichloromethane, and 1.3mL of 4mol·L -1 Hydrochloric acid / dioxane, stirred at room temperature for 1 h, a large amount of white precipitate was seen, the solvent was immediately removed using a rotary evaporator, and washed with dichloromethane 3 times, and the excess solvent was removed by negative pressure of an oil pump to obtain a pure white solid (254.4 mg, 85%), namely DCA-Ala-NH2, which was frozen and stored for later use;
[0042] (2) The preparation process of the intermediate product DSPE-TK-COOH is as follows: 1,2-distearoyl-sn-glycero-3-phospho-ethanolamine (DSPE) (1 mmol, 748.1 mg) was dissolved in 10 mL of chloroform at 70°C. After cooling to room temperature, 3-(propane-2,2-diylbis(thioalkanediyl))dipropionic acid (TK-COOH) (3 mmol, 756.9 mg) was added and shaken to dissolve. EDCI (3 mmol, 575.1 mg) and N-hydroxysuccinimide (3 mmol, 345.3 mg) were added and the reaction was stirred in a water bath at 40°C for 48 hours. h, the product was purified by column chromatography to obtain a white solid (884.2 mg, 90%), namely DSPE-TK-COOH, which was frozen and stored for future use;
[0043] (3) The preparation process of ROS-responsive decitabine prodrug DSPE-TK-DCA-Ala is as follows: DSPE-TK-COOH (1 mmol, 982.4 mg) was dissolved in 5 mL of chloroform, and DCA-Ala-NH2 (1.5 mmol, 448.9 mg) was dissolved in 5 mL of DMF. The two were mixed dropwise, and EDCI (3 mmol, 575.1 mg) and NHS (3 mmol, 345.3 mg) were added. The mixture was stirred in a water bath at 37 °C for 24 h. The product was purified by column chromatography to obtain a white solid (884.6 mg, 70%), namely DSPE-TK-DCA-Ala.
[0044] like Figure 4 Shown is the H NMR spectrum of the ROS-responsive decitabine prodrug compound.
[0045] The preparation method of DCA-101 is as follows:
[0046] (1) The preparation process of the intermediate product DCA-Ala-NH2 is shown in Example 1;
[0047] (2) The preparation process of intermediate 101 is as follows: 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) (1 mmol, 744.1 mg) was dissolved in 10 mL of chloroform at 70°C. After cooling to room temperature, 3-(propane-2,2-diylbis(thioalkanediyl))dipropionic acid (TK-COOH) (3 mmol, 756.9 mg) was added and shaken to dissolve. EDCI (3 mmol, 575.1 mg) and N-hydroxysuccinimide (NHS) (3 mmol, 345.3 mg) were added and the reaction was stirred in a water bath at 40°C for 48 hours. h, the product was purified by column chromatography to obtain a white solid (870.7 mg, 89%), namely the intermediate 101, which was frozen and stored for future use;
[0048] (3) The preparation process of DCA-101 is as follows: the intermediate product 101 (1 mmol, 978.4 mg) was dissolved in 5 mL of chloroform, and DCA-Ala-NH2 (1.5 mmol, 448.9 mg) was dissolved in 5 mL of DMF. The two were mixed dropwise, and EDCI (3 mmol, 575.1 mg) and NHS (3 mmol, 345.3 mg) were added. The mixture was stirred in a water bath at 37 °C for 24 h. The product was purified by column chromatography to obtain a white solid (1070.7 mg, 85%), namely DCA-101.
[0049] .
[0050] The preparation method of DCA-102 is as follows:
[0051] (1) The preparation process of the intermediate product DCA-Ala-NH2 is shown in Example 1;
[0052] (2) The preparation process of intermediate 102 is as follows: 1,2-Dimyristoyl-sn-glycero-3-phosphoethanolamine (DMPE) (1 mmol, 635.9 mg) was dissolved in 10 mL of chloroform at 70°C. After cooling to room temperature, 3-(propane-2,2-diylbis(thioalkanediyl))dipropionic acid (TK-COOH) (3 mmol, 756.9 mg) was added and shaken to dissolve. EDCI (3 mmol, 575.1 mg) and N-hydroxysuccinimide (NHS) (3 mmol, 345.3 mg) were added and the reaction was stirred in a water bath at 40°C for 48 hours. h, the product was purified by column chromatography to obtain a white solid (739.7 mg, 85%), namely the intermediate 102, which was frozen and stored for future use;
[0053] (3) The preparation process of DCA-102 is as follows: the intermediate product 102 (1 mmol, 870.2 mg) was dissolved in 5 mL of chloroform, and DCA-Ala-NH2 (1.5 mmol, 448.9 mg) was dissolved in 5 mL of DMF. The two were mixed dropwise, and EDCI (3 mmol, 575.1 mg) and NHS (3 mmol, 345.3 mg) were added. The mixture was stirred in a water bath at 37 °C for 24 h. The product was purified by column chromatography to obtain a white solid (978.7 mg, 85%), namely DCA-102.
[0054] .
[0055] The preparation method of DCA-103 is as follows:
[0056] (1) The preparation process of the intermediate product DCA-Ala-NH2 is shown in Example 1;
[0057] (2) The preparation process of intermediate 103 is as follows: 1,2-Dilauroyl-sn-Glycero-3-Phosphatidylethanolamine (DLPE) (1 mmol, 579.8 mg) was dissolved in 10 mL of chloroform at 70°C. After cooling to room temperature, 3-(propane-2,2-diylbis(thioalkanediyl))dipropionic acid (TK-COOH) (3 mmol, 756.9 mg) was added and shaken to dissolve. EDCI (3 mmol, 575.1 mg) and N-hydroxysuccinimide (NHS) (3 mmol, 345.3 mg) were added and the reaction was stirred in a water bath at 40°C for 48 hours. h, the product was purified by column chromatography to obtain a white solid (708.2 mg, 87%), namely the intermediate 103, which was frozen and stored for future use;
[0058] (3) The preparation process of DCA-103 is as follows: the intermediate product 103 (1 mmol, 814.1 mg) was dissolved in 5 mL of chloroform, and DCA-Ala-NH2 (1.5 mmol, 448.9 mg) was dissolved in 5 mL of DMF. The two were mixed dropwise, and EDCI (3 mmol, 575.1 mg) and NHS (3 mmol, 345.3 mg) were added. The mixture was stirred in a water bath at 37 °C for 24 h. The product was purified by column chromatography to obtain a white solid (909.1 mg, 83%), namely DCA-103.
[0059] .
[0060] The preparation method of DCA-104 is as follows:
[0061] (1) The preparation process of the intermediate product DCA-Ala-NH2 is shown in Example 1;
[0062] (2) The preparation process of intermediate 104 is as follows: 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine (DPPE) (1 mmol, 692.0 mg) was dissolved in 10 mL of chloroform at 70°C. After cooling to room temperature, 3-(propane-2,2-diylbis(thioalkanediyl))dipropionic acid (TK-COOH) (3 mmol, 756.9 mg) was added and shaken to dissolve. EDCI (3 mmol, 575.1 mg) and N-hydroxysuccinimide (NHS) (3 mmol, 345.3 mg) were added and the reaction was stirred in a water bath at 40°C for 48 hours. h, the product was purified by column chromatography to obtain a white solid (824.4 mg, 89%), namely the intermediate 104, which was frozen and stored for future use;
[0063] (3) The preparation process of DCA-104 is as follows: the intermediate product 104 (1 mmol, 926.3 mg) was dissolved in 5 mL of chloroform, and DCA-Ala-NH2 (1.5 mmol, 448.9 mg) was dissolved in 5 mL of DMF. The two were mixed dropwise, and EDCI (3 mmol, 575.1 mg) and NHS (3 mmol, 345.3 mg) were added. The mixture was stirred in a water bath at 37 °C for 24 h. The product was purified by column chromatography to obtain a white solid (978.1 mg, 81%), namely DCA-104.
[0064] .
[0065] The preparation method of DCA-201 is as follows: (1) preparation of the intermediate product DCA-Ala-NH2;
[0066] (2) The preparation process of intermediate 201 is as follows: 1,2-distearoyl-sn-glycero-3-phospho-ethanolamine (DSPE) (1 mmol, 748.1 mg) was dissolved in 10 mL of chloroform at 70°C. After cooling to room temperature, 3,3-diselenodipionic acid (2.0 mmol, 608.2 mg) was added and shaken to dissolve. EDCI (3 mmol, 575.1 mg) and N-hydroxysuccinimide (NHS) (3 mmol, 345.3 mg) were added and stirred in a water bath at 40°C for 48 h. The product was purified by column chromatography to obtain a white solid (651.5 mg, 63%), which was intermediate 201. It was frozen and stored for future use.
[0067] (3) The preparation process of DCA-201 is as follows: the intermediate product 201 (1 mmol, 1034.1 mg) was dissolved in 5 mL of chloroform, and DCA-Ala-NH2 (1.5 mmol, 448.9 mg) was dissolved in 5 mL of DMF. The two were mixed dropwise, and EDCI (3 mmol, 575.1 mg) and NHS (3 mmol, 345.3 mg) were added. The mixture was stirred in a water bath at 37 °C for 24 h. The product was purified by column chromatography to obtain a solid powder (1065.5 mg, 81%), namely DCA-201.
[0068] .
[0069] The preparation method of DCA-202 is as follows: The preparation method of DCA-202 is as follows:
[0070] (1) The preparation process of the intermediate product DCA-Ala-NH2 is shown in Example 1;
[0071] (2) The preparation process of intermediate 202-1 is as follows: oxalyl chloride (2 mmol, 253.8 mg) and 3-hydroxypropionic acid (5 mmol, 450.5 mg) were mixed and placed in a round-bottom flask protected by nitrogen, anhydrous sodium carbonate (5 mmol, 530.0 mg) was added, and the mixture was reacted in an oil bath at 50°C for 24 h. Column chromatography was used for purification to obtain intermediate 202-1 (435.5 mg, 93%).
[0072] (3) The preparation process of intermediate 202-2 is as follows: dissolve distearoylphosphatidylethanolamine (1,2-distearoyl-sn-glycero-3-phospho-ethanolamine, DSPE) (1 mmol, 748.1 mg) in 10 mL chloroform at 70°C, cool to room temperature, add intermediate 202-1 (2.0 mmol, 468.3 mg), shake to dissolve, add EDCI (3 mmol, 575.1 mg) and N-hydroxysuccinimide (N-Hydroxy succinimide, NHS) (3 mmol, 345.3 mg), stir in a water bath at 40°C for 48 h, purify the product by column chromatography, and obtain solid powder (732.8 mg, 76%), namely intermediate 202-2, which is frozen for future use;
[0073] (4) The preparation process of DCA-202 is as follows: the intermediate product 202-2 (1 mmol, 964.2 mg) was dissolved in 5 mL of chloroform, and DCA-Ala-NH2 (1.5 mmol, 448.9 mg) was dissolved in 5 mL of DMF. The two were mixed dropwise, and EDCI (3 mmol, 575.1 mg) and NHS (3 mmol, 345.3 mg) were added. The mixture was stirred in a water bath at 37 °C for 24 h. The product was purified by column chromatography to obtain a solid powder (983.9 mg, 79%), namely DCA-202.
[0074] .
[0075] The preparation method of DCA-203 is as follows:
[0076] (1) The preparation process of the intermediate product DCA-Ala-NH2 is shown in Example 1;
[0077] (2) The preparation process of intermediate 203 is as follows: 1,2-distearoyl-sn-glycero-3-phospho-ethanolamine (DSPE) (1 mmol, 748.1 mg) was dissolved in 10 mL of chloroform at 70°C. After cooling to room temperature, 1,1'-ferrocenedicarboxylic acid (2.0 mmol, 548.2 mg) was added and shaken to dissolve. EDCI (3 mmol, 575.1 mg) and N-hydroxysuccinimide (NHS) (3 mmol, 345.3 mg) were added and stirred in a water bath at 40°C for 48 h. The product was purified by column chromatography to obtain a white solid (692.8 mg, 69%), which was intermediate 203. It was frozen and stored for future use.
[0078] (3) The preparation process of DCA-203 is as follows: the intermediate product 203 (1 mmol, 1004.1 mg) was dissolved in 5 mL of chloroform, and DCA-Ala-NH2 (1.5 mmol, 448.9 mg) was dissolved in 5 mL of DMF. The two were mixed dropwise, and EDCI (3 mmol, 575.1 mg) and NHS (3 mmol, 345.3 mg) were added. The mixture was stirred in a water bath at 37 °C for 24 h. The product was purified by column chromatography to obtain a solid powder (1028.3 mg, 80%), namely DCA-203.
[0079] .
[0080] The preparation method of DCA-204 is as follows:
[0081] (1) The preparation process of the intermediate product DCA-Ala-NH2 is shown in Example 1;
[0082] (2) The preparation process of intermediate 204 is as follows: 1,2-distearoyl-sn-glycero-3-phospho-ethanolamine (DSPE) (1 mmol, 748.1 mg) was dissolved in 10 mL of chloroform at 70°C. After cooling to room temperature, 3,3′-thiodipropionic acid (2.0 mmol, 356.4 mg) was added and shaken to dissolve. EDCI (3 mmol, 575.1 mg) and N-hydroxysuccinimide (NHS) (3 mmol, 345.3 mg) were added and stirred in a water bath at 40°C for 48 h. The product was purified by column chromatography to obtain a white solid (826.5 mg, 91%), which was intermediate 204. It was frozen and stored for future use.
[0083] (3) The preparation process of DCA-204 is as follows: the intermediate product 204 (1 mmol, 908.3 mg) was dissolved in 5 mL of chloroform, and DCA-Ala-NH2 (1.5 mmol, 448.9 mg) was dissolved in 5 mL of DMF. The two were mixed dropwise, and EDCI (3 mmol, 575.1 mg) and NHS (3 mmol, 345.3 mg) were added. The mixture was stirred in a water bath at 37 °C for 24 h. The product was purified by column chromatography to obtain a solid powder (880.3 mg, 74%), namely DCA-204.
[0084] .
[0085] The preparation method of DCA-206 is as follows: (1) preparation of the intermediate product DCA-Ala-NH2;
[0086] (2) The preparation process of intermediate 206 is as follows: 1,2-distearoyl-sn-glycero-3-phospho-ethanolamine (DSPE) (1 mmol, 748.1 mg) was dissolved in 10 mL of chloroform at 70°C. After cooling to room temperature, 2,2'-[propane-2,2-diylbis(thio)]diacetic acid (3 mmol, 672.9 mg) was added and shaken to dissolve. EDCI (3 mmol, 575.1 mg) and N-hydroxysuccinimide (3 mmol, 345.3 mg) were added and the reaction was stirred in a water bath at 40°C for 48 hours. h, the product was purified by column chromatography to obtain a white solid (878.0 mg, 92%), namely, the intermediate 206, which was frozen and stored for future use;
[0087] (3) The preparation process of DCA-206 is as follows: the intermediate product 206 (1 mmol, 954.4 mg) was dissolved in 5 mL of chloroform, and DCA-Ala-NH2 (1.5 mmol, 448.9 mg) was dissolved in 5 mL of DMF. The two were mixed dropwise, and EDCI (3 mmol, 575.1 mg) and NHS (3 mmol, 345.3 mg) were added. The mixture was stirred in a water bath at 37 °C for 24 h. The product was purified by column chromatography to obtain a solid powder (951.4 mg, 77%), namely DCA-206.
[0088] .
[0089] The preparation method of DCA-301 is as follows:
[0090] (1) The preparation process of the intermediate product DCA-Gaba-NH2 is as follows: Decitabine (DCA) (1 mmol, 228.1 mg) and N-Boc-γ-aminobutyric acid (Boc-γ-Gaba) (1.2 mmol, 243.9 mg) are dissolved in N,N-dimethylformamide (DMF), and 4-dimethylaminopyridine (DMAP) (3 mmol, 366.5 mg) and 1-ethyl-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI) (3 mmol, 575.1 mg) are reacted at room temperature for 24 h. After the reaction, the product is purified by column chromatography to obtain a slightly yellow oily substance (372.1 mg, 90%), namely DCA-Gaba-Boc. DCA-Gaba-Boc (1 mmol, 413.4 mg) was dissolved in 5 mL of dichloromethane, and 1.3 mL of 4 mol·L-1 hydrochloric acid / dioxane was added thereto. The mixture was stirred at room temperature for 1 h, and a large amount of white precipitate was precipitated. The solvent was immediately removed by rotary evaporator, and the mixture was washed with dichloromethane for 3 times. The excess solvent was removed by negative pressure of an oil pump to obtain a pure white solid (253.8 mg, 81%), namely DCA-Gaba-NH2, which was stored frozen for later use.
[0091] (2) The preparation process of the intermediate product DSPE-TK-COOH is shown in Example 1;
[0092] (3) The preparation process of DCA-301 is as follows: DSPE-TK-COOH (1 mmol, 982.4 mg) was dissolved in 5 mL of chloroform, and DCA-Gaba-NH2 (1.5 mmol, 470.0 mg) was dissolved in 5 mL of DMF. The two were mixed dropwise, and EDCI (3 mmol, 575.1 mg) and NHS (3 mmol, 345.3 mg) were added. The mixture was stirred in a water bath at 37 °C for 24 h. The product was purified by column chromatography to obtain a white solid (868.8 mg, 68%), namely DCA-301.
[0093] .
[0094] The preparation method of DCA-302 is as follows:
[0095] (1) The preparation process of the intermediate product DCA-Ava-NH2 is as follows: Decitabine (DCA) (1 mmol, 228.1 mg) and 5-(N-tert-butyloxycarbonylamino) valeric acid (Boc-5-Ava-OH) (1.2 mmol, 260.7 mg) were dissolved in N,N-dimethylformamide (DMF), and 4-dimethylaminopyridine (DMAP) (3 mmol, 366.5 mg) and 1-ethyl-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI) (3 mmol, 575.1 mg) were reacted at room temperature for 24 h. After the reaction, the product was purified by column chromatography to obtain a slightly yellow oily substance (371.9 mg, 87%), namely DCA-Ava-Boc. DCA-Ava-Boc (1 mmol, 427.5 mg) was dissolved in 5 mL of dichloromethane, and 1.3 mL of 4 mol·L-1 hydrochloric acid / dioxane was added thereto. The mixture was stirred at room temperature for 1 h, and a large amount of white precipitate was precipitated. The solvent was immediately removed by rotary evaporator, and the mixture was washed with dichloromethane for 3 times. The excess solvent was removed by negative pressure of an oil pump to obtain a pure white solid (255.3 mg, 78%), namely DCA-Ava-NH2, which was stored frozen for later use.
[0096] (2) The preparation process of the intermediate product DSPE-TK-COOH is shown in Example 1;
[0097] (3) The preparation process of DCA-302 is as follows: DSPE-TK-COOH (1 mmol, 982.4 mg) was dissolved in 5 mL of chloroform, and DCA-Ava-NH2 (1.5 mmol, 491.0 mg) was dissolved in 5 mL of DMF. The two were mixed dropwise, and EDCI (3 mmol, 575.1 mg) and NHS (3 mmol, 345.3 mg) were added. The mixture was stirred in a water bath at 37 °C for 24 h. The product was purified by column chromatography to obtain a white solid (904.2 mg, 70%), namely DCA-302.
[0098] .
[0099] The preparation method of DCA-303 is as follows:
[0100] (1) The preparation process of the intermediate product DCA-AHP-NH2 is as follows: Decitabine (DCA) (1 mmol, 228.1 mg) and 7-(N-tert-butyloxycarbonylamino)heptanoic acid (BOC-7-AHP-OH) (1.2 mmol, 294.4 mg) were dissolved in N,N-dimethylformamide (DMF), and 4-dimethylaminopyridine (DMAP) (3 mmol, 366.5 mg) and 1-ethyl-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI) (3 mmol, 575.1 mg) were reacted at room temperature for 24 h. After the reaction, the product was purified by column chromatography to obtain a slightly yellow oily substance (400.8 mg, 88%), namely DCA-AHP-Boc. DCA-AHP-Boc (1 mmol, 455.5 mg) was dissolved in 5 mL of dichloromethane, and 1.3 mL of 4 mol·L -1 Hydrochloric acid / dioxane, stirred at room temperature for 1 h, a large amount of white precipitate was seen, the solvent was immediately removed using a rotary evaporator, and washed with dichloromethane 3 times, and the excess solvent was removed by negative pressure of an oil pump to obtain a pure white solid (259.4 mg, 73%), namely DCA-AHP-NH2, which was frozen and stored for later use;
[0101] (2) The preparation process of the intermediate product DSPE-TK-COOH is shown in Example 1;
[0102] (3) The preparation process of DCA-303 is as follows: DSPE-TK-COOH (1 mmol, 982.4 mg) was dissolved in 5 mL of chloroform, and DCA-AHP-NH2 (1.5 mmol, 533.1 mg) was dissolved in 5 mL of DMF. The two were mixed dropwise, and EDCI (3 mmol, 575.1 mg) and NHS (3 mmol, 345.3 mg) were added. The mixture was stirred in a water bath at 37 °C for 24 h. The product was purified by column chromatography to obtain a white solid (871.1 mg, 66%), namely DCA-303.
[0103] .
[0104] Example 2
[0105] Prescription composition:
[0106] ;
[0107] Preparation process: DCA-LNP was prepared by nanoprecipitation method. Accurately weigh 5 times the amount of ALC-0315, DOPC, cholesterol, DSPE-PEG 2000 DSPE-TK-DCA-Ala, add 0.5 mL of a mixed solution of tetrahydrofuran (THF) and methanol (1:1), dissolve in a water bath with ultrasound, and use it as the organic phase. Add 0.9 mL of pH 6.8 buffer to a 10 mL round-bottom flask, add 0.1 mL of the organic phase dropwise into the aqueous phase under vigorous magnetic stirring, stir evenly, and dialyze to remove the residual organic solvent to obtain DCA-LNP.
[0108] Example 3
[0109] Prescription composition:
[0110] ;
[0111] Preparation process: miR-LNP was prepared by nanoprecipitation method. Accurately weigh 5 times the amount of ALC-0315, DOPC, cholesterol and DSPE-PEG 2000 , add 0.5 mL of a mixed solution of tetrahydrofuran (THF) and methanol (1:1), dissolve in a water bath with ultrasonication, and use it as the organic phase. Add 0.9 mL of pH 6.8 buffer and 10 μg of miR-150 to a 10 mL round-bottom flask, add 0.1 mL of the organic phase dropwise into the aqueous phase under vigorous magnetic stirring, stir evenly, and dialyze to remove the residual organic solvent to obtain miR-LNP.
[0112] Example 4
[0113] Prescription composition:
[0114] ;
[0115] Preparation process: DCA@miR-LNP was prepared by nanoprecipitation method. Accurately weigh 5 times the amount of ALC-0315, DOPC, cholesterol, DSPE-PEG 2000DSPE-TK-DCA-Ala, add 0.5 mL of a mixed solution of tetrahydrofuran (THF) and methanol (1:1), dissolve in a water bath with ultrasonication, and use it as the organic phase. Add 0.9 mL of pH 6.8 buffer and 10 μg of miR-150 to a 10 mL round-bottom flask, add 0.1 mL of the organic phase dropwise into the aqueous phase under vigorous magnetic stirring, stir evenly, and dialyze to remove the residual organic solvent to obtain DCA@miR-LNP.
[0116] Example 5
[0117] Prescription composition:
[0118] ;
[0119] Preparation process: DCA@miR-LNP (SM-102) was prepared by nanoprecipitation method. Accurately weigh 5 times the amount of SM-102, DOPC, cholesterol, DSPE-PEG 2000 DSPE-TK-DCA-Ala, add 0.5 mL of a mixed solution of tetrahydrofuran (THF) and methanol (1:1), dissolve in a water bath with ultrasonication, and use it as the organic phase. Add 0.9 mL of pH 6.8 buffer and 10 μg of miR-150 to a 10 mL round-bottom flask, add 0.1 mL of the organic phase dropwise into the aqueous phase under vigorous magnetic stirring, stir evenly, and dialyze to remove the residual organic solvent to obtain DCA@miR-LNP (SM-102).
[0120] The preparations prepared in Example 4 and Example 5 were taken and the particle sizes were measured using a Malven Zetasizer. Figure 5 As shown, Example 4 prepared nearly spherical lipid nanoparticles with smaller particle size and uniform PDI, with an average particle size of about 140 nm and a PDI less than 0.3. Figure 6 As shown, the lipid nanoparticles prepared in Example 5 have an average particle size of about 190 nm and a larger particle size distribution range than those prepared in Example 4, which proves that under the same prescription conditions, ALC-0315 is better than SM-102 in selecting ionizable lipids.
[0121] The preparation prepared in Example 3 was taken, mixed with plasma and placed in a 37°C air bath. After incubation with plasma for 0 h, 0.5 h, 1 h, 2 h, 4 h, 6 h, and 8 h, SDS solution was added, mixed, and placed in a 60°C water bath for 5 min to inactivate the enzyme in the plasma. Then, heparin sodium solution was added, mixed evenly, and incubated at room temperature for 10 min to extract siRNA in the preparation, and then the samples were subjected to nucleic acid electrophoresis.
[0122] Figure 7 The brightness of the free siRNA band displaced from the preparation was close to that at 0 h, indicating that the preparation could effectively isolate the loaded siRNA from the enzymes in the plasma within 8 h and maintain the stability of the nucleic acid drug.
[0123] The preparation prepared in Example 4 was added to a 100 kDa dialysis tube, and a PBS group and PBS+H2O2 (25 mM) were set up respectively. The mixture was shaken in a shaker at 37°C for release. Samples were taken at 0, 0.25, 0.5, 1, 2, 4, 8, 18, and 24 h, and the release of decitabine was detected by HPLC.
[0124] Figure 8 It was shown that in the presence of H2O2, the release rate and cumulative release amount of decitabine at the release focus were significantly higher than those under normal conditions; this shows that lipid nanoparticles have less chemotherapeutic toxicity to healthy cells in vivo, but have stronger toxicity to rapidly proliferating AML cells.
[0125] C1498 cells in good growth state were taken and inoculated into a 96-well cell culture plate at 5000 cells / well (culture medium volume was 100 μL), and cultured for 24 h. Lipid nanoparticles with miRNA concentrations of 66 μg / ml, 33 μg / ml, 16.5 μg / ml, 8.3 μg / ml, 4.2 μg / ml, 2.1 μg / ml, and 1.1 μg / ml were prepared respectively according to the preparation methods in Example 2, Example 3, and Example 4; lipid nanoparticles with DSPE-TK-DCA-Ala (in terms of DCA concentration) concentrations of 0.18 mg / ml, 0.09 mg / ml, 0.045 mg / ml, 0.023 mg / ml, 0.012 mg / ml, 0.006 mg / ml, and 0.003 mg / ml; and lipid nanoparticles loaded with the above two drugs, the concentrations of which were the same as those of the lipid nanoparticles loaded with one of the drugs. 10 μL of the above lipid nanoparticles were added to a 96-well plate according to the grouping, and the culture was continued for 24 h. The cell activity was detected by CCK-8 method, and the synergy index CI value was calculated using Compusyn software.
[0126] Fig. 9 The CI value of the combined application of miRNA and DCA is shown, indicating that the combined application of the two has an obvious synergistic effect.
[0127] C1498 cells in good growth state were taken and inoculated into a 12-well cell culture plate at 100,000 cells / well (culture medium volume was 1 ml), and the culture was continued for 24 h. The lipid nanoparticles in Example 2, Example 3, Example 4 and Example 5 were taken respectively, and 25 μL of lipid nanoparticles were added to each well according to the grouping. The culture was continued for 24 h, and the cell apoptosis ratio was examined using a cell apoptosis kit.
[0128] Fig.10 The values of C1498 cell apoptosis induced by each group of preparations are shown, indicating that this lipid nanoparticle can effectively kill AML cells, and further proves that miRNA and DCA have a synergistic effect. It also shows that lipid nanoparticles using ALC-0315 have a stronger effect of inducing cell apoptosis than lipid nanoparticles prepared using SM-102.
Claims
1. A ROS-responsive decitabine prodrug compound, characterized in that: The compound structural formula is as follows: ; Among them, X is or , n is an integer from 0 to 7; Y is the ROS response key, or ; Z is a phosphatidylethanolamine compound, which is distearoylphosphatidylethanolamine, dioleoylphosphatidylethanolamine, dimyristoylphosphatidylethanolamine, dilauroylphosphatidylethanolamine, dipalmitoylphosphatidylethanolamine; a is the connecting bond between X and Y, which is an ester bond or an amide bond, and the structure is , ; b is the connecting bond between Y and Z, which is an amide bond, and the structure is .
2. The decitabine prodrug compound according to claim 1, characterized in that Z is: 、 、 、 、 。 3. The decitabine prodrug compound according to claim 1, characterized in that: The compound has the following structure: 。 4. A method for preparing the decitabine prodrug compound according to claim 1, characterized in that: The following steps are involved: (1) ; (2) ; (3) ; (4) The intermediate compound 2 is reacted with the intermediate compound 3 through an amidation reaction, or the intermediate compound 3 is reacted with decitabine through an esterification reaction to prepare the decitabine prodrug represented by the general formula I.
5. Use of the decitabine prodrug compound according to claim 1 in the preparation of a medicament for treating hematological malignancies.
6. The use according to claim 5, characterized in that: The blood malignancy is acute myeloid leukemia, myelofibrosis, myelodysplastic syndrome, lymphoma or chronic myeloid leukemia.
7. The use according to claim 5, characterized in that: The drug is a lipid composition loaded with a decitabine prodrug compound; the lipid composition consists of an ionizable lipid material, other lipid materials and a decitabine prodrug compound.
8. The use according to claim 7, characterized in that: The lipid composition is loaded with a gene drug, and the gene drug is selected from one or more of siRNA, miRNA, mRNA, ASO, cricRNA, ssRNA, shRNA, and ssDNA.
9. The use according to claim 7, characterized in that: The ionizable lipid is one of Dlin-MC3-DMA, SM-102, and ALC-0315; the other lipid materials are dioleoyl phosphatidylcholine, hydrogenated soybean phosphatidylglycerol, egg phosphatidylglycerol, egg phosphatidylinositol, hydrogenated soybean phosphatidylethanolamine, phosphatidylethanolamine, soybean phosphatidylcholine, soybean phosphatidylglycerol, soybean phosphatidylserine, soybean phosphatidylinositol, hydrogenated soybean phosphatidylserine, soybean phosphatidylethanolamine, soybean phosphatidic acid, hydrogenated egg phosphatidylcholine, hydrogenated egg phosphatidylglycerol, egg phosphatidylserine, hydrogenated egg phosphatidylinositol, hydrogenated egg phosphatidylserine, hydrogenated phosphatidylethanolamine, hydrogenated phosphatidic acid, hydrogenated soybean phosphatidylcholine, hydrogenated soybean phosphatidyl Inositol, hydrogenated soybean phosphatidic acid, dipalmitoylphosphatidylcholine, distearoylphosphatidylinositol, egg phosphatidylcholine, dimyristoylphosphatidylcholine, dimyristoylphosphatidylglycerol, dipalmitoylphosphatidylglycerol, distearoylphosphatidylcholine, distearoylphosphatidylglycerol, phosphatidic acid, dioleylphosphatidyl-ethanolamine, palmitoylstearoylphosphatidylcholine, dipalmitoylphosphatidic acid, palmitoylstearoylphosphatidylglycerol, monooleoyl-phosphatidylethanolamine, tocopherol, ammonium salts of fatty acids, ammonium salts of phospholipids, ammonium salts of glycerides, dilauroylethylphosphocholine, distearoylphosphatidylserine, dimyristoylethylphosphocholine, dipalmitoylethylphosphocholine, distearoylethylphosphocholine, N-(2,3-di-(9- (Z)-octadecenyloxy)-prop-1-yl-N,N,N-trimethylammonium chloride, 1,2-bis(oleyloxy)-3-(trimethylammonium)propane, distearoylphosphatidylglycerol, dimyristoylphosphatidic acid, distearoylphosphatidic acid, dimyristoylphosphatidylinositol, dipalmitoylphosphatidylinositol, dimyristoylphosphatidylserine, dipalmitoylphosphatidylserine, myristoyl lysolecithin, palmitoyl lysolecithin, stearoyl lysolecithin, distearoylphosphatidylethanolamine-polyethylene glycol, phosphatidylcholine-polyethylene glycol, phosphatidylethanolamine-polyethylene glycol, distearoylphosphatidylcholine-polyethylene glycol, cholesterol, lanosterol, sitosterol, stigmasterol, ergosterol and one or more other functionalized phospholipids or sterol water-soluble derivatives.
10. The use according to claim 7, characterized in that: The composition is prepared by a liposome extrusion method, a thin film hydration method, a nanoprecipitation method, a microfluidics method, an impact jet mixing method, a thin film dispersion method, a reverse phase evaporation method, a double emulsion method and a solvent injection method, a hot melt method, a freeze drying method, a spray drying method, a supercritical reverse phase evaporation method, a dialysis method, a solvent volatilization method or a freeze drying method.
Citation Information
Patent Citations
Synthesis of decitabine
CN104211743A
Method of producing 2'-deoxy-5-azacytidine (decitabine)
TW200936604A
